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Edited by Jesus AvilaAbstract TAR DNA-binding protein-43 (TDP-43) is a highly
conserved, ubiquitously expressed nuclear protein that was re-
cently identiﬁed as the disease protein in frontotemporal lobar
degeneration with ubiquitin-positive inclusions (FTLD-U) and
amyotrophic lateral sclerosis (ALS). Pathogenic TDP-43 gene
(TARDBP) mutations have been identiﬁed in familial ALS kin-
dreds, and here we report a TARDBP variant (A90V) in a
FTLD/ALS patient with a family history of dementia. Signiﬁ-
cantly, A90V is located between the bipartite nuclear localiza-
tion signal sequence of TDP-43 and the in vitro expression of
TDP-43-A90V led to its sequestration with endogenous TDP-
43 as insoluble cytoplasmic aggregates. Thus, A90V may be a
genetic risk factor for FTLD/ALS because it predisposes nuclear
TDP-43 to redistribute to the cytoplasm and form pathological
aggregates.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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A90V1. Introduction
Frontotemporal lobar degeneration (FTLD) refers to a clin-
ically, genetically and pathologically heterogeneous group of
neurodegenerative diseases that account for up to 20% of pre-
senile dementia cases. Clinically, FTLD is characterized by
behavioral and/or language dysfunction [1–3], but it also canCorresponding author. Address: Center for Neurodegenerative Dis-
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doi:10.1016/j.febslet.2008.05.024ieties. Puco-occur with movement abnormalities such as parkinsonism
and motor neuron disease, including the most common type,
amyotrophic lateral sclerosis (ALS) [4,5]. Although neurode-
generative tauopathies account for many familial and sporadic
cases of FTLD, those cases with ubiquitin-positive tau- and a-
synuclein-negative inclusions (UBIs) make up the most com-
mon neuropathological subtype of FTLD, i.e. FTLD-U [6,7].
Recently, the transactive response (TAR) DNA-binding pro-
tein 43 (TDP-43) was identiﬁed as the major disease protein
in UBIs that accumulate in the central nervous system
(CNS) of patients with FTLD-U as well as in patients with
sporadic and familial ALS [8], but not in the majority of pa-
tients with familial ALS (FALS) due to SOD-1 gene mutations
[8–12]. These data provided compelling evidence that FTLD-U
and ALS represent a clinicopathological spectrum of the same
neurodegenerative disorder, i.e. TDP-43 proteinopathy, and
this view is supported by the recent detection of several path-
ogenic TARDBP mutations in a number of FALS kindreds
[13–16]. TDP-43, encoded by the TARDBP gene on chromo-
some 1, is a highly conserved, ubiquitously expressed nuclear
protein implicated in repression of gene transcription, inhibi-
tion of exon splicing and interactions with splicing factors
and nuclear bodies [17,18]. Under physiological conditions,
TDP-43 is predominately localized to the nucleus; however,
pathological TDP-43 forms inclusions in neuronal perikarya
and neurites, suggesting that the redistribution and sequestra-
tion of TDP-43 in the cytoplasm is a pathogenic mechanism
[8]. Moreover, we have identiﬁed a speciﬁc bipartite nuclear
localization signal (NLS) sequence in the amino terminal do-
main of TDP-43 that is required for nuclear targeting [19].
Over-expression of TDP-43 with mutated NLS sequence
(DNLS mutants) not only re-directed TDP-43 to the cyto-
plasm, but also reduced its solubility, resulting in the accumu-
lation of cytoplasmic aggregates, high Mr smears and C-
terminal fragments of TDP-43 similar to those seen in
FLTD-U/ALS cases [19]. Thus, these data imply that pertur-
bation of nuclear and cytoplasmic traﬃcking of TDP-43 leads
to the formation of cytoplasmic aggregates with morphologicalblished by Elsevier B.V. All rights reserved.
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[19]. Therefore, to demonstrate physiological relevance of in-
creased cytoplasmic TDP-43 as a potential pathogenic mecha-
nism, we investigated whether genetic variant(s) with defective
TARDBP NLS sequences are found in FTLD patients with or
without ALS and if such variant(s) perturbed TDP-43 distribu-
tion in the nucleus and cytoplasm.2. Methods
2.1. DNA sequencing
Genomic DNA was extracted from blood of living patients or from
postmortem brains using standard methods (Qiagen Inc., Valencia,
CA). The TARDBP gene was screened for mutations in a cohort of pa-
tients from University of California at San Francisco (UCSF). This in-
cluded 134 patients with clinical FTLD or FTLD/ALS, as well as in
autopsy cases with conﬁrmed TDP-43 pathology and neuropathologi-
cal diagnoses of ALS (n = 2) and FTLD-U or FTLD plus MND
(n = 12). Autopsy cases were conducted at the Center for Neurodegen-
erative Disease Research at the University of Pennsylvania (UPenn).
Cases with mutations in the progranulin gene were excluded. The cod-
ing region of TARDBP, consisting of exons 2–5 and the ﬁrst 531 nucle-
otides (nt) of exon 6, as well as at least 100 nt of the ﬂanking intronic
regions of each exon were fully sequenced in both directions. Primers
used to amplify part or all of each exon were selected using Primer3
software and are available upon request.
Ampliﬁcation reactions (50 ll) were performed with 200 ng DNA
using AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster
City, CA) and 0.8 lM (ﬁnal concentration) each primer. Touchdown
ampliﬁcation protocol used consisted of 95 C (10 min), followed by
14 cycles of 95 C (30 s), 60 C (exons 4–6) or 58 C (exons 2 and 3)
with a reduction of 0.5 C per cycle (30 s), 72 C (1 min) and 20 cycles
of 95 C (30 s), 53 C (30 s), 72 C (1 min), with a ﬁnal 72 C extension
(5 min). Ampliﬁcation products were puriﬁed using AMPure (Agen-
court Bioscience, Beverly, MA) followed by single pass bidirectional
sequencing performed by Agencourt Bioscience or CEQ8000 (Beck-
man Coulter, Fullerton, CA) with Beckman Coulter sequencing re-
agents. Results were analyzed using Mutation Surveyor software
(SoftGenetics, PA).2.2. SNP genotyping of TARDBP variant
Genotyping of control samples for TARDBP c.269C > T (p.A90V)
was performed using a TaqMan chemistry-based allelic discrimination
assay with ‘‘Assay by Design’’ (Applied Biosystems) probes on an Ap-
plied Biosystems 7900 followed by analysis with Sequence Detection
System 2.2.1 software (Applied Biosystems). A total of 1385 control
samples were obtained from the following sources: 276 controls from
the Coriell Institute (Neurologically Normal Caucasian control panels,
Camden, NJ; mean age 70 y), 48 clinical controls (mean age 76 y) from
the Alzheimer Disease Core Center at UPenn, 42 normal postmortem
brain samples (mean age 69 y) from the UPenn brain bank, 638 normal
controls (mean age 63 y) from the Mayo Clinic Scottsdale and 381 nor-
mal controls (mean age 76 y) from the University of Washington. The
DNA sample with the variant identiﬁed by DNA sequencing served as
a positive control.2.3. TDP-43 constructs
cDNA encoding human TDP-43 (Accession no. NM007375) in the
plasmid pENTR-221 was obtained from Invitrogen (Carlsbad, CA).
The addition of a myc epitope tag to the 5 0-end of TDP-43 was
achieved by PCR, using the primers; 5 0-AAGCTTGATGGAA-
CAAAAACTCATCTCGGAAGAGGATCTGTCTGAATATATTC-
GGGTAACC-3 0 and 5 0-TCTAGAGCTACATTCCCCAGCCAGA-
AGACTTAGA-3 0. The PCR product was cloned into the pGEM-T
vector (Promega, Madison, WI). Following sequence analysis, the
PCR product was then subcloned into the plasmid pcDNA 3.1 (Invit-
rogen) using restriction sites HindIII and XbaI, creating pcDNA 3.1/
myc-TDP-43-WT. Site-directed mutations (see below) were generated
using the plasmid pcDNA 3.1/myc-TDP-43-WT as a template.2.4. Site-directed mutagenesis of TDP-43
Site-directed mutagenesis (Quikchange kit; Strategene, La Jolla, CA)
was used to create DNLS1 [19] and A90V missense mutation in the lon-
gest human TDP-43 isoform. Sequence of the mutagenized oligonucle-
otides are as follows: A90V: 5 0-G GAT GAG ACA GAT GTT TCA
TCA GCA GTG AAA GTG-30. All constructs were subjected to se-
quence analysis.
2.5. Cell culture and transfection
QBI-293 cells were grown in Dulbeccos modiﬁed Eagles medium
supplemented with 10% fetal bovine serum, 1% penicillin–streptomycin
and 1% L-glutamate. QBI-293 cells were transfected using the Amaxa
Nucleofector system (Amaxa Inc., Gaithersburg, MD) or Lipofect-
amine 2000 (Invitrogen) according to the manufacturers instructions.
2.6. Antibodies
Antibodies used here included: rabbit anti-TDP-43 antibody raised
to recombinant TDP-43 (Protein Tech Group, Chicago, IL); anti-
myc mAb (9E10, Santa Cruz Biotechnology, Santa Cruz, CA) and
an anti-a- tubulin mAb (Sigma, St. Louis, MO).2.7. Immunoﬂuorescence studies
Cells were ﬁxed in 4% paraformaldehyde in phosphate-buﬀered sal-
ine (PBS), permeabilized with 0.02% or 0.2% Triton X-100 (Sigma) in
PBS for 10 min, blocked with 5% powdered milk in PBS for 2-h and
incubated overnight with primary antibody at 4 C. Primary antibod-
ies were visualized with secondary antibodies conjugated with either
Alexa Fluor 488 or Alexa Fluro 594 (Vector Laboratories, Burlingame,
CA) and nuclei were detected using DAPI. All cells were analyzed
using a Nikon TE-2000-E (Nikon, Tokyo, Japan) and images were
captured using a CoolSnap-HQ camera (Photometrics, Tuscon, AZ).
All micrographs show individual cells representative of the total cell
population. For all experiments, at least four separate experiments
were performed in duplicate.
2.8. Solubility and biochemical analysis
To examine the solubility proﬁle of TDP-43, sequential extractions
were performed. Cells were washed twice with PBS, lysed in cold RIPA
buﬀer, and sonicated. Cell lysates were cleared by centrifugation at
40000 rpm for 30 min at 4 C to generate the RIPA soluble samples.
To prevent carry over the resulting pellets were washed twice (i.e. re-
sonicated and re-centrifuged). Only the supernatants from the ﬁrst cen-
trifugation were analyzed and all supernatants produced from the sec-
ond and third wash step were discarded. RIPA insoluble pellets were
then extracted with urea buﬀer (7 M urea, 2 M thiourea, 4% 3-[(3-cho-
lamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS),
30 mM Tris, pH 8.5), sonicated and centrifuged at 40000 rpm for
30 min at 22 C. Protease inhibitors were added to all buﬀers prior
to use (1 mM PMSF and a cocktail of protease inhibitors). Protein
concentration was determined by bicinchoninic acid method (Pierce,
Rockford, IL) and all proteins were resolved by 10% SDS–PAGE
and transferred to nitrocellulose membranes. Following transfer, nitro-
cellulose membranes were blocked in 5% powdered milk and incubated
in the primary antibody overnight at 4 C. Primary antibodies were de-
tected with horseradish peroxidase-conjugated anti-IgG antibody
(Jackson ImmunoResearch, Wegate, PA) and blots were developed
with Renaissance Enhanced Luminal Reagents (NEN Life Science
Products, Boston, MA). Digital images were acquired using a Fuji
Film Intelligent Darkbox II (Fuji Systems, Stamford, CT).3. Results and discussion
Genetic evaluation of TARDBP was completed on 148 pa-
tients with a clinical and/or autopsy proven diagnosis of FTLD
or FTLD/ALS and identiﬁed a single living patient with a
c.269C > T (A90V) substitution in exon 3. This 72-year-old
Caucasian with a family history of dementia (Supplementary
Fig. 1) presented clinically with symptoms consisting of slowly
progressive FTLD/ALS (age of onset 57 y). Additional family
members (deceased, aﬀected or living unaﬀected) were unavail-
F
T
(
(
m
m
2254 M.J. Winton et al. / FEBS Letters 582 (2008) 2252–2256able for testing and no autopsies have been performed in the
probands family to study the neuropathological changes
linked to the A90V TARDBP variant. Therefore, association
of this variant with disease in the family could not be con-
ﬁrmed at this time. Testing of 1385 age-matched controls for
the c.269C > T substitution by SNP genotyping identiﬁed the
variant in a single control case (one out of 1385 cases;ig. 1. The A90V TDP-43 variant partially disrupts nuclear localization (a–i). T
DP-43-WT (WT), myc-TDP-43-DNLS1 (DNLS1) or myc-TDP-43-A90V (A9
a, d, g) anti-TDP-43 (red) and (b, e, h) anti-myc (green) antibodies or merged
j). Quantiﬁcation of the cellular localization, nuclear (nuc; black bars) vs. cytop
yc-TDP-43-WT (WT), myc-TDP-43-NLS1 (DNLS1) or myc-TDP-43-A90V
yc-TDP-43-WT transfected cells (P 6 0.05). Error bars represent S.E.M.0.07%), 76-year-old at inclusion of the study indicating that
this amino acid substitution may be a polymorphism in the
TARDBP gene. However, based on the functional data pre-
sented below we speculate that A90V may increase the risk
of FTLD/ALS.
As the A90V variant is located between the bipartite NLS se-
quence of TDP-43, we examined its functional consequences inwo-color immunoﬂuorescence of QBI-293 cells transfected with myc-
0V). Seventy-two hours following transfection, cells were stained with
(c, f, i). Nuclei were labeled with DAPI stain (blue). Scale bar; 20 lm.
lasmic (cyto; white bars), of TDP-43 in QBI-293 cells transfected with
(A90V). Asterisks (***) represents signiﬁcant diﬀerences compared to
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293 cells and two-color immunoﬂuorescence was performed
on cells 72-h post-transfection. Both myc-TDP-43-WT and
myc-TDP-43-DNLS1 were used as controls and as reported
previously [19], myc-TDP-43-WT was localized exclusively to
the nucleus (Fig. 1a–c) and myc-TDP-43-DNLS1 was detected
primarily in the cytoplasm (Fig. 1d–f). However, myc-TDP-43-
A90V was detected both in the nucleus and in the cytoplasm of
a subset of cells, suggesting only a partial disruption of TDP-
43 nuclear localization by the alanine to valine substitution
(Fig. 1g–i). Quantitative analysis of transfected cells showed
that 78% and 22% of myc-TDP-43-A90V expressing cells
showed nuclear and cytoplasmic localization of TDP-43,
respectively (Fig. 1j). Further, since the A90V variant is lo-
cated in between the bipartite NLS sequence, and not directly
in the functional region, we hypothesize that this variant may
only cause a mild disruption in the nuclear localization of
TDP-43 and as a result the mislocalization of TDP-43 only oc-
curs in a sub-set of transfected cells.
To determine if myc-TDP-43-A90V accumulated as an insol-
uble pool and sequestered endogenous TDP-43, RIPA and
urea fractions of transfected cells were analyzed by immuno-
blot. Since myc-tagged TDP-43 protein migrated slower than
endogenous TDP-43 in SDS–PAGE, each could be analyzed
separately. At all time points examined, both endogenous
and myc-TDP-43-WT were recovered exclusively in the RIPA
fractions (Fig. 2a and b). Consistent with the expected DNLS
sequence disruption described previously [19], myc-TDP-43-
A90V was detected in the urea fraction as well as in the RIPA
fraction 24 h post-transfection and by 72 h both endogenous
and the myc-TDP-43-A90V proteins were recovered in the
insoluble urea fraction (compare Fig. 2a with b). Thus, the
myc-TDP-43-A90V genetic variant showed partial NLS se-
quence disruption and caused a similar but milder phenotype
like that seen in the myc-TDP-43-DNLS mutants [19] includingFig. 2. Endogenous TDP-43 is sequestered in the insoluble fraction
with the expression of myc-TDP-43-A90V. Immunoblots of RIPA (R)
and urea (U) extracted fractions (a) 24-h or (b) 72-h post-transfection
with empty vector (CTRL), myc-TDP-43-WT (WT), myc-TDP-43-
DNLS1 (DNLS1) or myc-TDP-43-A90V (A90V) with anti-TDP-43
antibody. Alpha-tubulin was used as a loading control.sequestration of endogenous TDP-43 by myc-TDP-43-A90V
in the urea fraction (Fig. 2a and b).
The identiﬁcation of a human genetic variant in the region
between the bipartite NLS sequence, in concert with results
from in vitro cell biology experiments gives credence to the no-
tion that functional disruption of the highly conserved NLS se-
quence could increase the risk for FTLD/ALS. Unfortunately,
no biological samples were available from other members of
the probands family for genetic analysis; however, there is a
very strong documented family history of dementia. Further-
more, the clinical presentation of both FTLD and ALS in
the proband is consistent with the current hypothesis that
FTLD and ALS represent two extremes of a clinicopatholog-
ical spectrum of disease, TDP-43 proteinopathies [8].
We have reported previously that over-expression of TDP-
43-DNLS mutants in vitro recapitulated the biochemical phe-
notype found in human neurodegenerative TDP-43 proteinop-
athies [19]. In concert with this ﬁnding a similar, but milder,
phenotype was also observed with A90V over-expression.
However, as our manuscript was in preparation, the A90V
TDP-43 variant was identiﬁed in a 53-year-old control (1/372
cases screened) [14] as well as an unspeciﬁed control (1/360)
[15]. Thus, as of today, this variant has been found in one af-
fected and three control subjects. Therefore, we cannot exclude
the possibility that A90V represents a rare benign polymor-
phism. However, our in vitro data and the strong family his-
tory of dementia suggest that the A90V variant maybe a
potential genetic risk factor for FTLD. Similar to other known
disease risk factor genes, characteristics and lifestyle of the per-
son, and environmental and additional genetic factors can con-
tribute to the development of the disease. Reduced penetrance
and variation in expressivity may also play a role in the dis-
ease-associated risk of the A90V variant. This is consistent
with our in vitro data as the mislocalization of TDP-43 was
observed in only a subset of transfected cells. Thus, the pres-
ence of the A90V variant may increase the likelihood of devel-
oping FTLD/ALS.
The recent discovery of multiple pathogenic TARDBPmuta-
tions in several FALS kindreds [13–16] further supports the
importance of TDP-43 in the etiology and pathogenesis of
ALS; however, unlike the A90V TDP-43 substitution, these re-
cently identiﬁed TARDBPmutations are localized to the C-ter-
minus of TDP-43 and thus, are likely to cause the disease
through diﬀerent mechanisms. Current literature suggests that
the presence of disease segregating mutations in TDP-43 are
rare, and to date, minimal neuropathological data from af-
fected family members has been published. Therefore, further
genetic analysis needs to be completed in more familial cases
of FTLD/ALS before we can conclusively comment on the ge-
netic and mechanistic consequences of TDP-43 mutations, as
well as the TDP-43 A90V variant.
Furthermore, although TDP-43 inclusions are found in the
nucleus and cytoplasm of diseased cells in association with nu-
clear clearing of TDP-43, it remains uncertain how TARDBP
mutations or TDP-43 pathology causes neurodegeneration in
FTLD-U and ALS. Rapid progress is being made regarding
the normal and pathological biology of TDP-43 and this will
accelerate eﬀorts to develop new and more eﬀective therapies
for neurodegenerative TDP-43 proteinopathies.
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